{"id":765575,"date":"2023-06-22T16:08:53","date_gmt":"2023-06-22T20:08:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/"},"modified":"2023-06-22T16:08:53","modified_gmt":"2023-06-22T20:08:53","slug":"compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/","title":{"rendered":"Compass Therapeutics to be Added to the Russell 2000\u00ae\u00a0and Russell 3000\u00ae\u00a0Indexes"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, June  22, 2023  (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that it will be added to the Russell 2000<sup><strong>\u00ae<\/strong><\/sup> and Russell 3000<sup><strong>\u00ae<\/strong><\/sup> Indexes as part of the Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023.<\/p>\n<p>Membership in the US all-cap Russell 3000<sup><strong>\u00ae<\/strong><\/sup> Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000<sup><strong>\u00ae<\/strong><\/sup> Index or small-cap Russell 2000<sup><strong>\u00ae<\/strong><\/sup> Index as well as membership and inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.<\/p>\n<p>\u201cWe are pleased to be added to the Russell Indexes,\u201d said Vered Bisker-Leib, President &amp; COO of Compass Therapeutics. \u201cThe inclusion of Compass will enhance trading activity of our stock and broaden our exposure to the investment community, which may help accelerate our efforts to develop next generation antibodies into transformative cancer therapies that improve patients\u2019 lives.\u201d<\/p>\n<p>Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $12 trillion in assets are benchmarked against Russell\u2019s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.<\/p>\n<p>For more information about the Russell U.S. Indexes and the Russell index reconstitutions, visit the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nTAqUkemZ9h_FaK2J11hVNhnirSbfah7MNwFyV_VgIUi3JWJVJB968EZLAmw_JMNXJhVPvBvpBuVe38P4e2izQzv_vi_DPJ1xeC1yOTRAj-PYL6l2QHGXICP5DGFkf1YSjKd_HQvbcb56KWew5eihw==\" rel=\"nofollow noopener\" target=\"_blank\">FTSE Russell website<\/a>.<\/p>\n<p>\n        <strong>About Compass Therapeutics <\/strong>\n      <\/p>\n<p>Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass\u2019s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vYGmclcy6KF_7d8v9oxS9EGNfsLQtnCd-NtnqVltRpJ_bIHNmOJ6VTU_w31iAuNZm3RkRXe30uAa-_VzN7EaGo2CVshXoIY8xm8ktlGEoD07wD3jL4fVkJz_KVxoEbdgHDjCN7f5fER1RDqzQXCn2yI8OhOJX3_SYqje3Ll0ZUAVqGhYSLg7jkQ6Eg2r0XD7gtNu0ieKuRbA3WoIP--iu7q0vJCrcV2K5cop5kklr2ye66rK_mdb2kXG0-8g010RBby_bTsNP1QG51yDO1o86b9mIxnznsUO6pfu4HsC_Q2q3WWimz9-lsvMmNb8ZLyJ4o0Q5GnRJoLwxOZfJM8jK9ro0AprHYWdagzXfihwakpOpro37hPrJaVJoVbSpTNX9cr0-iJMy3ACyz6__e4nrXAy3bE64Lmeq2FDAY0I4Wp01GCP3CRoMoA_lRzPCSk830qTP5jq5dzOwbP8kGuJImymHxHLHfkrEt8eifwBjCRXXr0fapCQZwp7ba9j0B1-tHIAH1MHGpUgED3_Vk8YMFNX5pwLf0wzrwQ7iMh09cjawDXdcn7ZVvmOrRARGkYepac8FdbLswaAgGt-Y-QPNU2Ru23mXWCmxnciFerifDvkOaM_NYeA64AmyXduKk6REaJ3KkHHNFWVLxOFoNZKf9knXtZ0rvZKRbEAU9EuMpE=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.compasstherapeutics.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>\n        <em>This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Compass\u2019s financial position, potential trading and investment activities, and statements regarding Compass\u2019s product candidates and the development thereof. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Compass\u2019s ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, Compass\u2019s ability to identify additional product candidates for development, Compass\u2019s ability to develop, complete clinical trials for, obtain approvals for and commercialize any of its product candidates, competition in the industry in which Compass operates and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Compass files with the SEC available at www.sec.gov, including without limitation Compass\u2019s latest Form 10-Q and subsequent filings with the SEC.<\/em>\n      <\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s3sUkYEaqfVS4yKyuRAa6x9EGwRkC06ZPo3NZ5MwxE10Pch1DfkIbx_FPe4EiSra51Xe1F9lXZCA-IY55HUnLzknMKdGKNF2otw37eGUlST_MLbtQnv6BglSsS0X0bvC\" rel=\"nofollow noopener\" target=\"_blank\">ir@compasstherapeutics.com<\/a>\n      <\/p>\n<p>\n        <strong>Media Contact <\/strong><br \/>\n        <br \/>Anna Gifford, Communications Manager <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KgG4BKE1sTiWZQgr2Aplr60ItGn0N6ZmV5dG6IpLAixJVHOF5HIdUUmHHLh6yQ7IRP-lQaIZG6mr2a0glQDZ9XeWwW2YWtZ-eSJ26xy3ip_26r_Qs3QgF_Dovn4_x1Be\" rel=\"nofollow noopener\" target=\"_blank\">media@compasstherapeutics.com<\/a><br \/>617-500-8099<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTU0MiM1NjU2Njc4IzIyMDI0MjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YWY5OGI1MDAtOGY3OC00YzI5LTkyY2QtNGRlMTVkNWI4MWY5LTEyMTM5NzU=\/tiny\/Compass-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, June 22, 2023 (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that it will be added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes as part of the Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023. Membership in the US all-cap Russell 3000\u00ae Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000\u00ae Index or small-cap Russell 2000\u00ae Index as well as membership and inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. \u201cWe are &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Compass Therapeutics to be Added to the Russell 2000\u00ae\u00a0and Russell 3000\u00ae\u00a0Indexes&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-765575","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Compass Therapeutics to be Added to the Russell 2000\u00ae\u00a0and Russell 3000\u00ae\u00a0Indexes - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Compass Therapeutics to be Added to the Russell 2000\u00ae\u00a0and Russell 3000\u00ae\u00a0Indexes - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, June 22, 2023 (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that it will be added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes as part of the Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023. Membership in the US all-cap Russell 3000\u00ae Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000\u00ae Index or small-cap Russell 2000\u00ae Index as well as membership and inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. \u201cWe are &hellip; Continue reading &quot;Compass Therapeutics to be Added to the Russell 2000\u00ae\u00a0and Russell 3000\u00ae\u00a0Indexes&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-22T20:08:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTU0MiM1NjU2Njc4IzIyMDI0MjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Compass Therapeutics to be Added to the Russell 2000\u00ae\u00a0and Russell 3000\u00ae\u00a0Indexes\",\"datePublished\":\"2023-06-22T20:08:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/\"},\"wordCount\":644,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MTU0MiM1NjU2Njc4IzIyMDI0MjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/\",\"name\":\"Compass Therapeutics to be Added to the Russell 2000\u00ae\u00a0and Russell 3000\u00ae\u00a0Indexes - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MTU0MiM1NjU2Njc4IzIyMDI0MjI=\",\"datePublished\":\"2023-06-22T20:08:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MTU0MiM1NjU2Njc4IzIyMDI0MjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MTU0MiM1NjU2Njc4IzIyMDI0MjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Compass Therapeutics to be Added to the Russell 2000\u00ae\u00a0and Russell 3000\u00ae\u00a0Indexes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Compass Therapeutics to be Added to the Russell 2000\u00ae\u00a0and Russell 3000\u00ae\u00a0Indexes - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/","og_locale":"en_US","og_type":"article","og_title":"Compass Therapeutics to be Added to the Russell 2000\u00ae\u00a0and Russell 3000\u00ae\u00a0Indexes - Market Newsdesk","og_description":"BOSTON, June 22, 2023 (GLOBE NEWSWIRE) &#8212; Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that it will be added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes as part of the Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023. Membership in the US all-cap Russell 3000\u00ae Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000\u00ae Index or small-cap Russell 2000\u00ae Index as well as membership and inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. \u201cWe are &hellip; Continue reading \"Compass Therapeutics to be Added to the Russell 2000\u00ae\u00a0and Russell 3000\u00ae\u00a0Indexes\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-22T20:08:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTU0MiM1NjU2Njc4IzIyMDI0MjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Compass Therapeutics to be Added to the Russell 2000\u00ae\u00a0and Russell 3000\u00ae\u00a0Indexes","datePublished":"2023-06-22T20:08:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/"},"wordCount":644,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTU0MiM1NjU2Njc4IzIyMDI0MjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/","name":"Compass Therapeutics to be Added to the Russell 2000\u00ae\u00a0and Russell 3000\u00ae\u00a0Indexes - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTU0MiM1NjU2Njc4IzIyMDI0MjI=","datePublished":"2023-06-22T20:08:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTU0MiM1NjU2Njc4IzIyMDI0MjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTU0MiM1NjU2Njc4IzIyMDI0MjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/compass-therapeutics-to-be-added-to-the-russell-2000-and-russell-3000-indexes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Compass Therapeutics to be Added to the Russell 2000\u00ae\u00a0and Russell 3000\u00ae\u00a0Indexes"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765575","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=765575"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765575\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=765575"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=765575"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=765575"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}